NEW YORK (GenomeWeb) – Elucigene Diagnostics, a Manchester, UK-based molecular test provider, will seek US Food and Drug Administration clearance next year for a cystic fibrosis screening assay specific to the American population.
CEO Mark Street-Docherty said that the multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
